EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors

Antoine Italiano, Teresa García Manrique, Enrique Grande Pulido, Katie Kerrigan, Aude Fléchon, Julia Martínez Pérez, Bogdan Żurawski, Muhammad Furqan, Oscar Juan-Vidal, Ulka Vaishampayan, Charlene Fares, Bruno Fang und 8 weitere

Frontiers in Oncology · 22.04.2026 · 16

DOI: 10.3389/fonc.2026.1786385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 22.04.2026. Verfasst von Antoine Italiano und 19 weiteren Autor:innen. Beteiligte Einrichtung: Département d'oncologie médicale - Sarcomes, Centre Régional de Lutte Contre le Cancer (CLCC) Institut Bergonié, Bordeaux, France. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Novel treatments are needed to improve the poor prognosis of metastatic cancers. The ELEVATE Lung&UC study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC), metastatic small cell lung cancer (mSCLC), and metastatic urothelial carcinoma (mUC).

Methods

This phase II, open-label, multi-arm study enrolled patients who had received 1–2 (mNSCLC, mSCLC) or 2–3 prior lines of therapy (mUC) in the locally advanced/metastatic setting. A safety run-in (SRI) cohort (mNSCLC/mSCLC/mUC) followed by a phase II cohort (three groups: mNSCLC, mSCLC, mUC) were planned. Primary endpoints were incidence of treatment-emergent adverse events (TEAEs; SRI and phase II) and objective response rate (ORR; phase II).

Results

The SRI cohort (n = 9) had no dose-limiting toxicities. In phase II (mNSCLC, 29 patients; mSCLC, 42 patients; mUC, 26 patients), ORRs were 17.2% (mNSCLC), 4.8% (mSCLC), and 3.8% (mUC). Grade ≥3 magrolimab-related TEAE rates were 48.3% (mNSCLC), 47.6% (mSCLC), and 57.7% (mUC). A fatal TEAE suspected as magrolimab related (intracranial hemorrhage) occurred in one patient with mSCLC and brain metastasis (phase II). The study was closed early, which limited the interpretation of results due to short follow-up and limited endpoint maturity.

Discussion

Adding magrolimab to docetaxel had manageable toxicity but no meaningful improvement in efficacy. These results provide insight into the safety and efficacy of anti-CD47–containing therapies and reinforce the need for treatments that address the unmet needs of patients with previously treated metastatic solid tumors.

Schlagwörter

Stichwörter der Autor:innen

anti-CD47docetaxelmagrolimabmetastatic non-small cell lung cancermetastatic small cell lung cancermetastatic urothelial carcinoma

Autor:innen und Institutionen

  • Département d'oncologie médicale - Sarcomes, Centre Régional de Lutte Contre le Cancer (CLCC) Institut Bergonié, Bordeaux, France.
  • Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Servicio de Oncología Médica, MD Anderson Cancer Center, Madrid, Spain.
  • Division of Medical Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States.
  • Department of Medical Oncology, Centre Léon Bérard Centre Régional de Lutte Contre le Cancer, Lyon, France.
  • Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.

Förderung

  • Gilead Sciences

Zitieren

APA

Italiano, A., García Manrique, T., Grande Pulido, E., Kerrigan, K., Fléchon, A., Martínez Pérez, J., Żurawski, B., Furqan, M., Juan-Vidal, O., Vaishampayan, U., Fares, C., Fang, B., Vicuna, B., Greillier, L., Subbiah, V., Dong, M., Song, K., Zhang, Y., Kim, Y., & Paz-Ares, L. (2026). Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1786385

Vancouver

Italiano A, García Manrique T, Grande Pulido E, Kerrigan K, Fléchon A, Martínez Pérez J, et al. Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1786385

BibTeX
@article{Italiano2026,
  author = {Italiano, Antoine and García Manrique, Teresa and Grande Pulido, Enrique and Kerrigan, Katie and Fléchon, Aude and Martínez Pérez, Julia and Żurawski, Bogdan and Furqan, Muhammad and Juan-Vidal, Oscar and Vaishampayan, Ulka and Fares, Charlene and Fang, Bruno and Vicuna, Brian and Greillier, Laurent and Subbiah, Vivek and Dong, Mei and Song, Kai and Zhang, Yiran and Kim, Young and Paz-Ares, Luis},
  title = {Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1786385}
}
Kostenlos starten →